COG-ANBL2131: A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma

Objective

This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma.

National Clinical Trial (NCT) Number: 06172296

National Library of Medicine clinicaltrials.gov Website Address: https://clinicaltrials.gov/study/NCT06172296

Location: Essentia Health Cancer Centers

Research Study Categories

• Pediatric Oncology Studies

Specialties

• Brain Cancer

Contact

Cancer Clinical Trials at 218-786-3308 or 844-681-7944, [email protected]